Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) has announced the adoption of a shareholder rights plan (SRP) on April 14, 2025, to ensure fair treatment of all shareholders in the event of an unsolicited take-over bid or acquisition of control. Each common share outstanding as of the effective date will have one right attached to it under the SRP. Shareholders, excluding the acquiring person and its related parties, will be able to exercise their rights to purchase additional common shares at a substantial discount to the market price if rights become exercisable under the SRP.
The SRP is subject to the acceptance of the Toronto Stock Exchange and requires ratification by the company's shareholders within six months of its effective date. A summary of the principal terms and conditions of the SRP will be provided in the company’s management information circular to be mailed to shareholders prior to the meeting. The full SRP will be available under the company’s profile on the SEDAR+ website and the EDGAR website.
Bausch Health Companies Inc. is a global pharmaceutical company focused on various healthcare segments, including gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, through its controlling interest in Bausch + Lomb Corporation. The company aims to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees, and investors. The market has reacted to these announcements by moving the company's shares 0.9% to a price of $4.38. For the full picture, make sure to review Bausch Health's 8-K report.
